B2C Drugs E-commerce Platform Yao123 Wins RMB 120 Mln Series A

Vcbeat.net, 7/05/17

Sinopharm Online, operator of online and mobile B2C pharmaceuticals e-commerce platform Yao123.com, has completed RMB 120 mln in Series A funding from Yunfeng Capital and Langsheng Investment, according to an announcement from Sinopharm Online parent China National Pharmaceutical Group.

According to Sinopharm Online CEO Wang Letian, this round of funding will be used for offline sales and distribution resource integration, including the establishment of pharmacies in various locations across China.

Sinopharm Online was founded by China National Pharmaceutical Group in June 2015, and is positioned as a healthcare products and pharmaceuticals e-commerce platform focused primarily on B2C sales.

According to Wang Letian, Sinopharm Online's transaction volume has reached RMB 600 mln over the past 12 months.

Editor's Note: Yunfeng Capital is the private equity company co-founded by Alibaba Group (NYSE: BABA) founder Jack Ma.

Keywords: Sinopharm Online Wang Letian m-commerce wireless Yao123 e-commerce Internet funding B2C Series A Yunfeng Capital Langsheng online healthcare mobile healthcare

Feedback

Sending

Disclaimer

The information contained in this newsletter is based upon sources that Marbridge Consulting believes to be reliable, and we have made every effort to translate the original articles or article excerpts as faithfully as possible. However, Marbridge Consulting makes no warranty of and assumes no legal responsibility for the accuracy of either the original source material or the English language translations.

Marbridge Daily